DS-1123 / Daiichi Sankyo - LARVOL DELTA

Production of the renewable bioplastic poly-3-hydroxybutyrate from underutilized dairy waste streams through microbial bioconversion. (PubMed, J Dairy Sci) - "Five PHB-producing strains - Priestia megaterium DSM32, Cupriavidus necator DSM545, Azohydromonas lata DSM1123, Paraburkholderia fungorum DSM1749, and Halomonas halophila DSM4770 - were examined for growth and PHB production in ACW and SW...While PHB production from SW has been reported previously, this study is the first to demonstrate PHB production using ACW. These findings highlight the potential of SW and ACW as viable feedstocks for the microbial production of PHB, contributing to the valorization of dairy waste streams."

Journal

Study of DS-1123a in Advanced Solid Tumours (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Daiichi Sankyo Co., Ltd.; Active, not recruiting ➔ Completed; Trial primary completion date: Jul 2018 ➔ Nov 2017

Trial completion • Trial primary completion date • Biosimilar • Oncology • Solid Tumor

DS-Screen: Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer population. (ASCO-GI 2020) - "Moreover, eligible patients for the clinical trials of DS-1123 or DS-8201, which are FGFR2- or HER2-targeting anti-cancer agent respectively, were screened. This study showed insights into the expression status of FGFR2 and HER2 in GC and CRC as a large-scale prospective analysis. Seven patients who had no standard therapy could access exploratory new drug based on targetable agents through this study. Clinical trial information: 163380."

Clinical • FGFR2 • HER-2 • KRAS • NRAS